Scenic Biotech appoints Dr Philippe Dro as Chairman
Scenic Biotech has announced the appointment of Dr Philippe Dro as its independent Chairman. Dr Dro replaces Dr Ulrich Grau, who retires from the Board of Directors.
Swiss-based Dr Dro is trained in industrial pharmacy and finance. He has built a successful career in the European biotech and medtech sectors, serving on the boards of several start-ups and scaleups, initiating and executing notable strategic transactions. Alongside his role as Chairman of Scenic, he also serves as Chairman of Luciole Medical.
Dr Dro’s most recent experience has been in the vaccine sector; as Board member and CBO of Themis Biosciences, through to its sale to MSD in 2020; and as CEO and member of the Supervisory Board of GlycoVaxyn, leading it through to its acquisition by GSK. Before that, he led Endoart, a medtech company, as CEO and Chairman of the Board through a successful turnaround of the company leading to its acquisition by Allergan. As member of the founding team, he also worked at Axovan, a GPCR biotech which was acquired by Actelion in 2003. His earlier career experience in the pharmaceutical industry included managerial positions at Novartis, SkyePharma and Antares Pharma.
Dr Dro said: “I am passionate about the potential that innovative biotech has to improve outcomes for patients, enabling them to live healthy lives for longer. Scenic Biotech’s genetic modifier technology is driving a completely new class of drug targets.
“With the fundamentals in place, the company is poised for the next stage of its growth, to become a leading next-generation of science-led biotech companies that are changing medicine in the 21st century.”